Amgen stock heads into the open after a 4.34 percent gain
Published on 09/24/2026 at 07:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen stock closed at USD 410.24 on the Nasdaq on September 23, 2026, up 4.34 percent. The gain contrasted with a 1.13 percent decline in the Nasdaq Composite to 26,936.04 points.
September 23, 2026 in numbers
Amgen Inc. (ISIN US0311621009, Nasdaq: AMGN) traded between USD 398.53 and USD 412.76 and recorded volume of about 3.55 million shares on September 23, 2026. The closing price was USD 37.79 below the 52-week high of USD 447.03 and USD 140.47 above the 52-week low of USD 269.77.
The move followed positive late-stage trial news for dazodalibep in Sjogren disease and a higher price target from Jefferies. As FMP reported on September 23, 2026, the analyst raised the target to USD 410.00 after the experimental treatment met its primary late-stage trial goal.
Today, September 24, 2026
Amgen enters the session after the trial update and the analyst target change drove the previous session move. MarketBeat reported on September 23, 2026, that analysts maintained a Hold consensus, with an average 12-month target of USD 381.32; the report also said the next regulatory filing depends on another study.
